NSE: HIKAL | BSE: 524735

Expensive Performer

Download real time

414.60 -4.25 (-1.01%)

55.14% Gain from 52W Low

447.6K NSE+BSE Volume

NSE 15 Apr, 2025 3:31 PM (IST)

5,112.1

Market Cap

Above industry Median

1.1

Beta 1Year

High Volatility

Hikal Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for HIKAL, BSE:524735 Hikal Ltd.

Search Inside the pdf :

Hikal Ltd.

09 Sep 2024

414.60

-1.01%

Hikal Ltd.

Buy: Hikal Ltd.

Target

ICICI Direct

Hikal Ltd. has gained 37.22% in the last 1 Year

Hikal Ltd.

15 May 2024, 12:00AM

414.60

-1.01%

Hikal Limited

Buy: Hikal Ltd.

Recommendation Target

ICICI Direct

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

30 May 2023

414.60

-1.01%

Hikal Ltd

Hold: Hikal Ltd.

Target

ICICI Direct

Hikal Ltd. has gained 37.22% in the last 1 Year

Hikal Ltd.

03 Feb 2023

414.60

-1.01%

Hikal Ltd

Hold: Hikal Ltd.

Target

ICICI Direct

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

16 Aug 2022

414.60

-1.01%

Hikal Ltd

Hold: Hikal Ltd.

Recommendation Target

ICICI Direct

Hikal Ltd. has gained 37.22% in the last 1 Year

Hikal Ltd.

06 Jun 2022

414.60

-1.01%

BP Equities Hikal Ltd Q4FY22 Result Update

Hold: Hikal Ltd.

Target

BP Wealth

Hikal Ltd. has an average target of 420.00 from 1 broker.

Hikal Ltd.

06 Jun 2022

414.60

-1.01%

Hikal Ltd

Buy: Hikal Ltd.

ICICI Direct

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

21 Feb 2022

414.60

-1.01%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Maintain BUY on account of 1) consistency in offtake for crop protection CDMO, 2) expected recovery in Pharma, 3) Visibility capex. That said we continue to monitor developments on recent critical issues- 1) Surat (Gujrat) GIDC incident and 2) MPCB notice for Taloja....

Hikal Ltd. has gained 37.22% in the last 1 Year

Hikal Ltd.

21 Feb 2022

414.60

-1.01%

BP Equities Hikal Ltd Q3FY22 Result Update

Hold: Hikal Ltd.

Target

BP Wealth

Hikal posted revenue of INR 5,145mn with 11.1% YoY growth which was 8.7% above our estimate of INR 4733mn driven by the strong growth in the crop protection segment. On segmental performance: The crop protection segment grew by 27% (YoY) to INR 2464mn on the back of Increased sales volume of CDMO products and favourable price increases for certain products. Pharmaceutical segment revenue remained flat at INR 2,682mn on account of slower offtake by several customers due to the higher price of products led by rising input costs. Management expects raw material challenges to continue in the next few months and is working with their suppliers and customers to mitigate the price fluctuations. Higher operational cost combined with flat revenues resulted in a...